Processa Pharmaceuticals Inc. Company Profile
NASDAQ: PCSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Processa Pharmaceuticals at a glance
Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Vero Beach, FL. Processa Pharmaceuticals is led by Mr. George K. Ng Esq., J.D. and employs about 12 people. At a market capitalization of $4.4 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001533743, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Processa Pharmaceuticals do?
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Business description based on the company's public filings.
Company information
- Legal name
- Processa Pharmaceuticals Inc.
- Ticker
- NASDAQ: PCSA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. George K. Ng Esq., J.D.
- Employees
- 12
- Headquarters
- 601 21st Street, Vero Beach, FL, United States
- Phone
- 772 453 2899
- Website
- processapharmaceuticals.com
- Market cap
- $4.37M
- SEC CIK
- 0001533743
- Latest annual report
- 10-K/A · Apr 30, 2026
Companies similar to Processa Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CANFCan-Fite Biopharma Ltd ADR | 1.44 | -2.34% | $4.35M | vs PCSA |
| PULMPulmatrix Inc. | 1.27 | -10.56% | $4.64M | vs PCSA |
| SCNXScienture Holdings Inc. | 2.28 | -6.45% | $4.07M | vs PCSA |
| BLRXBioLineRx Ltd. ADR | 0.9639 | -8.20% | $4.80M | vs PCSA |
| LTRNLantern Pharma Inc. | 0.245 | -13.73% | $3.89M | vs PCSA |
| ALZNAlzamend Neuro Inc. | 0.7758 | -23.94% | $3.74M | vs PCSA |
| SILOSilo Pharma Inc. | 1.71 | -9.04% | $3.69M | vs PCSA |
| BGMSBio Green Med Solution Inc. | 0.553 | -9.48% | $3.66M | vs PCSA |